Salma Alvi, MD
Family Medicine · Hartford, CTNPI 1437462991
Payments from drug & device makers
Across 124 payments — averaging $26.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$661
- Pfizer$455
- AstraZeneca$438
- Mallinckrodt Hospital Products Inc.$222
- Otsuka America Pharmaceutical, Inc.$198
- Novartis$195
- plus $1K from 14 others
What the payments were for
- Food & beverage$3,323100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 23 | $661 |
| Pfizer | 18 | $455 |
| AstraZeneca(2 entities) | 22 | $438 |
| Mallinckrodt Hospital Products Inc. | 4 | $222 |
| Otsuka America Pharmaceutical, Inc. | 4 | $198 |
| Novartis | 10 | $195 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $189 |
| E.r. Squibb & Sons, L.L.C. | 8 | $157 |
| Boehringer Ingelheim | 5 | $134 |
| Actelion Pharmaceuticals US, Inc. | 1 | $125 |
| GSK | 1 | $125 |
| CSL Behring | 5 | $123 |
| Neurocrine Biosciences, Inc. | 3 | $69 |
| AbbVie | 2 | $57 |
| Alcresta Therapeutics, Inc. | 3 | $55 |
| Mylan Specialty L.p. | 2 | $48 |
| Ferring Pharmaceuticals Inc. | 1 | $23 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $18 |
| Merck | 1 | $18 |
| Gilead | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,323 in reported general payments places this provider in the 85th percentile of 588 family medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 456 | $139,258 |
| XifaxanRifaximin | 26 | $42,149 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $24,348 |
| XareltoRivaroxaban | 82 | $23,503 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 37 | $11,718 |
| MyrbetriqMirabegron | 39 | $10,723 |
| NuedextaDextromethorphan Hbr/Quinidine | 21 | $9,875 |
| ZenpepLipase/Protease/Amylase | 20 | $9,664 |
| FarxigaDapagliflozin Propanediol | 33 | $9,475 |
| LinzessLinaclotide | 16 | $9,469 |
| JardianceEmpagliflozin | 29 | $9,015 |
| EntrestoSacubitril/Valsartan | 23 | $7,909 |
| Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc | 55 | $6,578 |
| Incruse ElliptaUmeclidinium Bromide | 17 | $6,504 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 16 | $5,535 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo, Protonix | $455 | $154,559511 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $189 | $42,14926 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta | $125 | $35,98372 claims |
| Johnson & JohnsonXarelto | $661 | $23,50382 claims |
| Boehringer IngelheimJardiance, Tradjenta | $134 | $13,90747 claims |
| AstraZenecaFarxiga, Symbicort | $438 | $12,90347 claims |
| AbbVieLinzess | $57 | $9,46916 claims |
| NovartisEntresto | $195 | $7,90923 claims |
| MerckJanuvia | $18 | $4,35615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 588 family medicine providers in Connecticut.
Other family medicine in Hartford
- Mohammad Samer YounesHartford$20K
- Nieves HornbeckHartford$9K
- Mouhanad AyachHartford$8K
- Mark BelskyHartford$8K
- Charlecinth RobertsHartford$8K
- Debra GramlichStamford$292K
- Hadrian HolderNew Haven$213K
- Theodore BrunoDurham$201K
- Kenneth DardickStorrs$146K
- Raymond KurkerSouth Windsor$107K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.